Literature DB >> 1086708

Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease.

D C Case, J A Hansen, E Corrales, C W Young, B Dupont, C M Pinsky, R A Good.   

Abstract

Multiple in vivo and in vitro immune parameters were used to examine 52 untreated patients with Hodgkin's disease in all stages. A significant number (p less than 0.01) of patients in all stages demonstrated abnormalities in DNCB sensitization, peripheral blood lymphocyte response to phytohemagglutination, absolute lymphocyte count, absolute number of T cells (as measured by spontaneous rosette formation with sheep erythrocytes), and absolute number of B cells (as measured by immunofluorescence with polyvalent antiserum). The number of T and B cells fell progressively with each stage, but the proportion of T to B cells remained constant. Cutaneous anergy was found in STAGES III and IV. Depressed circulating immunoglobulins were found in a few patients in all stages. Neither the total lymphocyte number nor the number of T and B cells correlated with the measures of lymphocyte function (skin test reactivity, DNCB sensitization, mitogen response, or immunoglobulin levels). This study suggests that selective abnormalities in the immune system exist even in early Hodgkin's disease, involving the absolute number of circulating T and B lymphocytes and T-lymphocyte function. The study fails, however, to define a consistent pattern of immune defects as characteristic of Hodgkin's Disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1086708     DOI: 10.1002/1097-0142(197610)38:4<1807::aid-cncr2820380458>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  [Hodgkin's disease: effect of spenectomy on the immune status (author's transl)].

Authors:  V Diehl; M Schaadt; R J Kalden; C Hagedorn; N Schmidt; J Deinhardt
Journal:  Klin Wochenschr       Date:  1978-08-15

2.  Lymphocyte compartments in human spleen. An immunohistologic study in normal spleens and uninvolved spleens in Hodgkin's disease.

Authors:  W Timens; S Poppema
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

3.  Stage-dependent reduction in T colony formation in Hodgkin's disease. Coincidence with monocyte synthesis of prostaglandins.

Authors:  R S Bockman
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

4.  Increased luminol-enhanced chemiluminescence of blood monocytes and granulocytes in Hodgkin's disease.

Authors:  O Tullgren; R Giscombe; G Holm; B Johansson; H Mellstedt; M Björkholm
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

5.  Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.

Authors:  S M Hillinger; G P Herzig
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

6.  Impaired B-lymphocyte reactivity in patients with Hodgkin's disease and non-Hodgkin-lymphomas.

Authors:  H Rühl; B Enders; M Bur; G Sieber
Journal:  Blut       Date:  1981-05

7.  Affinity of IL-2 receptors and proliferation of mitogen activated lymphocytes in Hodgkin's disease.

Authors:  R N Damle; R J Tatake; S H Advani; S G Gangal
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

8.  Increased monocyte-mediated antibody-dependent cellular cytotoxicity (ADCC) in Hodgkin's disease.

Authors:  H Pehamberger; H Ludwig; P Pötzi; W Knapp
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

9.  The distribution of iron and iron binding proteins in spleen with reference to Hodgkin's disease.

Authors:  K J Britten; D B Jones; M De Sousa; D H Wright
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

10.  Frequencies of circulating B- and T-lymphocytes as indicators for stroke outcomes.

Authors:  Yanling Wang; Jihong Liu; Xuemei Wang; Zongjian Liu; Fengwu Li; Fenghua Chen; Xiaokun Geng; Zhili Ji; Huishan Du; Xiaoming Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-03       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.